A novel series of 2-pyrazoline derivatives were designed, synthesized, and evaluated for cholinesterase (ChE) inhibitory, Aβ anti-aggregating and neuroprotective activities. Among these, 3d, 3e, 3g, and 3h were established as the most potent and selective BChE inhibitors (IC50 = 0.5–3.9 μM), while 3f presented dual inhibitory activity against BChE and AChE (IC50 = 6.0 and 6.5 μM, respectively). Kinetic analyses revealed that 3g is a partial noncompetitive inhibitor of BChE (Ki = 2.22 μM), while 3f exerts competitive inhibition on AChE (Ki = 0.63 μM). The active compounds were subsequently screened for further assessments. 3f, 3g and 3h reduced Aβ1–42 aggregation levels significantly (72.6, 83.4 and 63.4%, respectively). In addition, 3f demonstrated outstanding neuroprotective effects against Aβ1–42-induced and H2O2-induced cell toxicity (95.6 and 93.6%, respectively). Molecular docking studies were performed with 3g and 3f to investigate binding interactions inside the active sites of BChE and AChE. Compounds 3g and 3f might have the multifunctional potential for use against Alzheimer's disease.
1 December 2019 in Turkish Journal of Pharmaceutical Sciences
The aim of this study was to synthesize, characterize, and screen some new 1-(4-((2-(4-substitutedphenyl)hydrazono)methyl)phenyl)-1H-1,2,4-triazole derivatives for their antimycobacterial activities. The target compounds (2a-h) were gained by condensation of 4-(1H-1,2,4-triazol-1-yl)benzaldehyde with appropriate phenylhydrazines. Their structures were elucidated by IR, 1H-NMR, and mass spectrometry. The antimycobacterial activities of the compounds were determined in vitro against Mycobacterium tuberculosis H37Rv. The biological assay results showed that the methylsulfonyl-substituted derivative 2f displayed the highest antimycobacterial activity in this series. Although the methylsulfonyl-substituted derivative exhibited significant antimycobacterial activity, none of the synthesized compounds was as effective as isoniazid, rifampin, ethambutol, and ciprofloxacin against M. tuberculosis.
Some thiazolo[4,5-d]pyrimidine-7(6H)-one derivatives were evaluated in vivo for their analgesic and anti-inflammatory activities. The results were compared with that of acetyl salicylic acid and phenylbutazone. Compounds 3b and 3h were the most active in the anti-inflammatory paw edema inhibition test. In terms of the analgesic activity (acetic acid writhing test), the most active compound was 2a followed by 31. The most active members of the series were investigated for their ED50 values and ulcerogenic potential. Thiazolo[4,5-d]pyrimidine als potentielle analgetische und entzündungshemmende Wirkstoffe Einige Thiazolo[4,5-d]pyrimidin-7(6H)-on-Derivative wurden auf ihre analgetische und entzündungshemmende Aktivität in vitro untersucht. Die Aktivität der Verbindungen wurde mit Acetylsalicylsäure und Phenylbutazon verglichen. Im Pfotenödem-Test zeigten die Substanzen 3b und 3h die beste Wirkung. Die höchsten analgetischen Aktivitäten wurden bei Substanz 2a und 3l beobachtet. Die ED 50-Werte der aktiven Substanzen und ihre ulzerogene Wirkung wurde untersucht.
In this study, by starting from ethyl 4-amino-2,3-dihydro-3-methyl-2-thio-xothiazole-5-carboxylate (1), the compounds having 2,3-dihydro-3-methyl-5-mercapto-6-methyl/ethyl-2-thioxothiazolo[4,5-d]pyrimidin-7(6H)-one (2a, 2b) structure and their 5-(4’-nonsubstituted/-substitutedbenzoylmethyl)thio derivatives (3a-h) were synthesized. The chemical structures of the compounds were proved by IR, 1H-NMR and elemental analysis data. In vitro antimicrobial activities of the synthesized compounds were investigated against some bacteria and yeasts using the microdilution method. In view of the antimicrobial activity results, a significant inhibitory effect was observed only for compound 2a against Gram-positive bacteria and yeasts, whereas the other compounds had no remarkable activity against the tested microorganisms. Synthese und antimikrobielle Bewertung neuer Thiazolo[4,5-d]pyrimidine In dieser Arbeit wurden zwei 2,3-Dihydro-3-methyl-5-mercapto-6-methyl/ ethyl-2-thioxothiazolo[4,5-d]pyrimidin-7 (6H)-one (2a, 2b) und ihre 5-(4’-Nonsubstituierte/-substituierte Benzoylmethyl) thio-Derivate (3a-h) hergestellt. Die Strukturaufklärung der Substanzen erfolgte durch IR- und 1H-NMR-Spektroskopie sowie durch Elementaranalyse. Die antimikrobielle Wirkung wurde in vitro gegen Gram-positive Bakterien und Candida-Hefen mit Hilfe von Reihenverdünnungstests untersucht. Substanz 2a zeigte gegen Grampositive Bakterien und Candida Hefen signifikant eine Aktivität, während die anderen Verbindungen keine nennenswerte Wirkung gegen die getesteten Mikroorganismen zeigten.